Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Key facts

Sponsor

Children's Oncology Group

Principal Investigator

Gregory Yanik, MD

Children's Oncology Group

Intervention

etanercept(biological)

Enrollment

39 enrolled

Eligibility

1-17 years · All sexes

Timeline

2006 – 2011

Study locations (26)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• Children's Oncology Group, Arcadia, California, United States
• Loma Linda University Medical Center, Loma Linda, California, United States
• Children's Hospital Colorado, Aurora, Colorado, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• All Children's Hospital, St. Petersburg, Florida, United States
• Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
• Childrens Memorial Hospital, Chicago, Illinois, United States
• Indiana University Cancer Center, Indianapolis, Indiana, United States
• Indiana University Medical Center, Indianapolis, Indiana, United States
• Children's Hospital-Main Campus, New Orleans, Louisiana, United States
• Johns Hopkins University, Baltimore, Maryland, United States
• C S Mott Children's Hospital, Ann Arbor, Michigan, United States
• University of Nebraska Medical Center, Omaha, Nebraska, United States
• Hackensack University Medical Center, Hackensack, New Jersey, United States
• +11 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chronic myeloid leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07354074
  Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
  Novartis Pharmaceuticals
• RECRUITINGNCT07375355
  Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
  Novartis Pharmaceuticals
• ENROLLING BY INVITATIONNCT07383298
  Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
  Qian Jiang
• RECRUITINGPHASE2NCT06817720
  Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
  M.D. Anderson Cancer Center
• RECRUITINGNCT07061145
  A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
  Azienda USL Reggio Emilia - IRCCS
• RECRUITINGPHASE2NCT06409936
  PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
  Gruppo Italiano Malattie EMatologiche dell'Adulto
• RECRUITINGPHASE2NCT06514534
  Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
  Novartis Pharmaceuticals
• RECRUITINGPHASE1NCT06787144
  ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
  Enliven Therapeutics

See all trials for Chronic myeloid leukemia →